Trial Outcomes & Findings for Effect of CT1812 Treatment on Brain Synaptic Density (NCT NCT03493282)

NCT ID: NCT03493282

Last Updated: 2023-09-07

Results Overview

Number of subjects reported with AEs and the number of AEs reported following administration of the IP summarized by treatment and grouped according to system organ class and preferred term, using descriptive statistics. Summaries of AEs were also presented by severity and by relationship to investigational product. In these summaries, subjects were counted only once per MedDRA term, for the AE of highest severity or least favorable relationship. Summaries were also presented of SAEs and of AEs leading to study withdrawal.

Recruitment status

COMPLETED

Study phase

PHASE1/PHASE2

Target enrollment

43 participants

Primary outcome timeframe

Up to 12 months

Results posted on

2023-09-07

Participant Flow

Location Type: Medical Clinic

Each participant was screened between Day -60 and Day -1 prior to study drug administration. Participants could choose to participate in the optional double-blind extension treatment period of an additional 24 weeks (337 days +/-2).as well as a follow up visit at 2 weeks after the final treatment visit. In the study, 43 patients were enrolled. 23 participants were randomized, and 20 were screen failures.

Participant milestones

Participant milestones
Measure
300 mg
High Dose CT1812 Active Treatment- CT1812 300 mg: CT1812 Administered as an oral capsule at dose levels of 300 mg
100 mg
Low Dose CT1812 Active Treatment -CT1812 100 mg: CT1812 Administered as an oral capsule at dose levels of 100 mg
Placebo
Matching Placebo Placebo: Matching Placebo
Primary Double-blind Study (180 Days)
STARTED
8
8
7
Primary Double-blind Study (180 Days)
COMPLETED
5
6
6
Primary Double-blind Study (180 Days)
NOT COMPLETED
3
2
1
Double-blind Extension Study (180 Days)
STARTED
3
6
4
Double-blind Extension Study (180 Days)
COMPLETED
3
6
4
Double-blind Extension Study (180 Days)
NOT COMPLETED
0
0
0

Reasons for withdrawal

Reasons for withdrawal
Measure
300 mg
High Dose CT1812 Active Treatment- CT1812 300 mg: CT1812 Administered as an oral capsule at dose levels of 300 mg
100 mg
Low Dose CT1812 Active Treatment -CT1812 100 mg: CT1812 Administered as an oral capsule at dose levels of 100 mg
Placebo
Matching Placebo Placebo: Matching Placebo
Primary Double-blind Study (180 Days)
Adverse Event
2
2
1
Primary Double-blind Study (180 Days)
Subject Moved
1
0
0

Baseline Characteristics

Effect of CT1812 Treatment on Brain Synaptic Density

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
300 mg
n=8 Participants
High Dose CT1812 Active Treatment- CT1812 300 mg: CT1812
100 mg
n=8 Participants
Low Dose CT1812 Active Treatment- CT1812 100 mg: CT1812
Placebo
n=7 Participants
Matching Placebo Placebo: Matching Placebo
Total
n=23 Participants
Total of all reporting groups
Age, Continuous
69.6 years
STANDARD_DEVIATION 10.9 • n=99 Participants
68.0 years
STANDARD_DEVIATION 9.3 • n=107 Participants
72.6 years
STANDARD_DEVIATION 5.8 • n=206 Participants
70.0 years
STANDARD_DEVIATION 8.8 • n=7 Participants
Sex: Female, Male
Female
4 Participants
n=99 Participants
4 Participants
n=107 Participants
3 Participants
n=206 Participants
11 Participants
n=7 Participants
Sex: Female, Male
Male
4 Participants
n=99 Participants
4 Participants
n=107 Participants
4 Participants
n=206 Participants
12 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
8 Participants
n=99 Participants
8 Participants
n=107 Participants
7 Participants
n=206 Participants
23 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants
1 Participants
n=7 Participants
Race (NIH/OMB)
White
8 Participants
n=99 Participants
8 Participants
n=107 Participants
6 Participants
n=206 Participants
22 Participants
n=7 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Weight
76.2 kg
STANDARD_DEVIATION 16.9 • n=99 Participants
85.6 kg
STANDARD_DEVIATION 5.0 • n=107 Participants
74.8 kg
STANDARD_DEVIATION 9.2 • n=206 Participants
79.0 kg
STANDARD_DEVIATION 12.1 • n=7 Participants
Height
170.3 cm
STANDARD_DEVIATION 9.9 • n=99 Participants
171.4 cm
STANDARD_DEVIATION 12.5 • n=107 Participants
172.1 cm
STANDARD_DEVIATION 12.1 • n=206 Participants
171.2 cm
STANDARD_DEVIATION 11.0 • n=7 Participants
Body Mass Index (BMI)
26.3 kg/m^2
STANDARD_DEVIATION 5.7 • n=99 Participants
29.5 kg/m^2
STANDARD_DEVIATION 4.1 • n=107 Participants
25.2 kg/m^2
STANDARD_DEVIATION 1.8 • n=206 Participants
27.1 kg/m^2
STANDARD_DEVIATION 4.5 • n=7 Participants

PRIMARY outcome

Timeframe: Up to 12 months

Population: Number of Subjects with Treatment Emergent Adverse Events (TEAE)

Number of subjects reported with AEs and the number of AEs reported following administration of the IP summarized by treatment and grouped according to system organ class and preferred term, using descriptive statistics. Summaries of AEs were also presented by severity and by relationship to investigational product. In these summaries, subjects were counted only once per MedDRA term, for the AE of highest severity or least favorable relationship. Summaries were also presented of SAEs and of AEs leading to study withdrawal.

Outcome measures

Outcome measures
Measure
300 mg
n=7 Participants
High Dose CT1812 CT1812 300 mg
100 mg
n=8 Participants
Low Dose CT1812 CT1812 100 mg
Placebo
n=6 Participants
Matching Placebo
All Subjects
n=21 Participants
Total
Number of TEAEs, Related TEAEs, SAEs, and Related SAEs
All TEAEs
7 Participants
8 Participants
6 Participants
21 Participants
Number of TEAEs, Related TEAEs, SAEs, and Related SAEs
Mild TEAEs
6 Participants
4 Participants
4 Participants
14 Participants
Number of TEAEs, Related TEAEs, SAEs, and Related SAEs
Moderate TEAEs
1 Participants
2 Participants
1 Participants
4 Participants
Number of TEAEs, Related TEAEs, SAEs, and Related SAEs
Severe TEAEs
0 Participants
2 Participants
1 Participants
3 Participants
Number of TEAEs, Related TEAEs, SAEs, and Related SAEs
Related TEAEs
4 Participants
3 Participants
4 Participants
11 Participants
Number of TEAEs, Related TEAEs, SAEs, and Related SAEs
TEAEs Leading to Treatment Discontinuation
2 Participants
2 Participants
1 Participants
5 Participants
Number of TEAEs, Related TEAEs, SAEs, and Related SAEs
SAEs
0 Participants
3 Participants
1 Participants
4 Participants
Number of TEAEs, Related TEAEs, SAEs, and Related SAEs
Related SAEs
0 Participants
0 Participants
0 Participants
0 Participants

SECONDARY outcome

Timeframe: Day 169

Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.

The Distribution Volume Ratio (DVR) was used to determine the correlations with the cognitive and functional endpoints. For 11C UCB J, the imaging outcome measure was DVR as produced by the Simplified Reference Tissue Model (SRTM2) using dynamic scan data from 0 to 60 min and the whole cerebellum as a reference region. Change from baseline is calculated as the observed value minus the baseline value. A negative change from baseline indicates the progression of disease.

Outcome measures

Outcome measures
Measure
300 mg
n=8 Participants
High Dose CT1812 CT1812 300 mg
100 mg
n=8 Participants
Low Dose CT1812 CT1812 100 mg
Placebo
n=7 Participants
Matching Placebo
All Subjects
Total
Change From Baseline in the Imaging of [11C] UCB-J PET Distribution Volume Ratio (DVR)
-0.043 ratio
Standard Error 0.020
-0.019 ratio
Standard Error 0.020
0.000 ratio
Standard Error 0.020

SECONDARY outcome

Timeframe: Day 169

Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.

For 18F FDG, the primary imaging outcome measure was the SUVR from 60-90 min post injection using whole cerebellum as a reference region. For SUVR, a composite region was determined, including: prefrontal, lateral temporal, posterior cingulate/precuneus, anterior cingulate, lateral parietal, medial temporal, and lateral occipital regions. Change from baseline is calculated as the observed value minus the baseline value. A negative change from baseline indicates the progression of the disease.

Outcome measures

Outcome measures
Measure
300 mg
n=8 Participants
High Dose CT1812 CT1812 300 mg
100 mg
n=8 Participants
Low Dose CT1812 CT1812 100 mg
Placebo
n=7 Participants
Matching Placebo
All Subjects
Total
Change From Baseline in the Imaging of [18F]FDG PET SUV Ratio (SUVR)
-0.084 ratio
Standard Error 0.017
-0.044 ratio
Standard Error 0.017
-0.053 ratio
Standard Error 0.017

SECONDARY outcome

Timeframe: Day 169

Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.

A composite region of AD affected brain regions was determined, including prefrontal, lateral temporal, posterior cingulate/precuneus, anterior cingulate, lateral parietal, medial temporal, and lateral occipital regions. Baseline is defined as the last measurement taken before the first dose of study drug. Change from baseline is calculated as the observed value minus the baseline value. A negative change from baseline indicates the progression of disease.

Outcome measures

Outcome measures
Measure
300 mg
n=8 Participants
High Dose CT1812 CT1812 300 mg
100 mg
n=8 Participants
Low Dose CT1812 CT1812 100 mg
Placebo
n=7 Participants
Matching Placebo
All Subjects
Total
Change From Baseline in Volumetric Magnetic Resonance Imaging (MRI)
-6.34 cm^3
Standard Error 3.49
-5.59 cm^3
Standard Error 3.51
-13.85 cm^3
Standard Error 3.39

SECONDARY outcome

Timeframe: Day 169

Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.

For resting state functional MRI, the outcome was ICC. With this approach a map of the total connectivity of each voxel to all other voxels was computed. For ICC, a composite region of AD affected brain regions was determined, including prefrontal, lateral temporal, posterior cingulate/precuneus, anterior cingulate, lateral parietal, medial temporal, and lateral occipital regions. Change from baseline is calculated as the observed value minus the baseline value. A negative change from baseline indicates the progression of disease.

Outcome measures

Outcome measures
Measure
300 mg
n=8 Participants
High Dose CT1812 CT1812 300 mg
100 mg
n=8 Participants
Low Dose CT1812 CT1812 100 mg
Placebo
n=7 Participants
Matching Placebo
All Subjects
Total
Change From Baseline in the Imaging of Functional MRI - Intrinsic Connectivity Contrast (ICC)
0.005 ratio
Standard Error 0.006
-0.008 ratio
Standard Error 0.006
-0.006 ratio
Standard Error 0.007

SECONDARY outcome

Timeframe: Day 169

Population: The Pharmacodynamic Analysis Set included all subjects who received the investigational product for 6 months and who had both a baseline CSF lumbar puncture and at least one post-dose result for any CSF concentrations.

Change from baseline in CSF Aβ 40, CSF Aβ 42, CSF tau, CSF phospho-tau, CSF neurogranin (NRGN), CSF synaptotagmin, CSF(SNAP25), and CSF neurofilament light (NFL). Change from baseline is calculated as the observed value minus the baseline value.

Outcome measures

Outcome measures
Measure
300 mg
n=7 Participants
High Dose CT1812 CT1812 300 mg
100 mg
n=5 Participants
Low Dose CT1812 CT1812 100 mg
Placebo
n=6 Participants
Matching Placebo
All Subjects
Total
Change From Baseline in the Cerebrospinal Fluid (CSF) Biomarkers
SNAP-25 (pg/ml)
-3.15 pg/ml
Standard Error 1.54
0.74 pg/ml
Standard Error 1.83
1.36 pg/ml
Standard Error 1.66
Change From Baseline in the Cerebrospinal Fluid (CSF) Biomarkers
Aβ 40 (pg/ml)
-594.0 pg/ml
Standard Error 381.57
517.70 pg/ml
Standard Error 445.24
222.25 pg/ml
Standard Error 397.27
Change From Baseline in the Cerebrospinal Fluid (CSF) Biomarkers
Aβ 42 (pg/ml)
-32.96 pg/ml
Standard Error 17.55
11.62 pg/ml
Standard Error 21.88
-13.90 pg/ml
Standard Error 19.66
Change From Baseline in the Cerebrospinal Fluid (CSF) Biomarkers
Tau (pg/ml)
-84.08 pg/ml
Standard Error 111.96
121.22 pg/ml
Standard Error 131.96
36.74 pg/ml
Standard Error 120.70
Change From Baseline in the Cerebrospinal Fluid (CSF) Biomarkers
Phospho-tau (pg/ml)
-7.71 pg/ml
Standard Error 12.60
5.80 pg/ml
Standard Error 14.91
-4.67 pg/ml
Standard Error 13.59
Change From Baseline in the Cerebrospinal Fluid (CSF) Biomarkers
NRGN (pg/ml)
-26.79 pg/ml
Standard Error 16.50
14.96 pg/ml
Standard Error 19.61
-5.54 pg/ml
Standard Error 17.77
Change From Baseline in the Cerebrospinal Fluid (CSF) Biomarkers
Synaptotagmin (pg/ml)
0.88 pg/ml
Standard Error 2.24
6.37 pg/ml
Standard Error 2.64
0.68 pg/ml
Standard Error 2.44
Change From Baseline in the Cerebrospinal Fluid (CSF) Biomarkers
NFL (pg/ml)
210.77 pg/ml
Standard Error 149.24
265.74 pg/ml
Standard Error 176.40
-24.02 pg/ml
Standard Error 164.56

SECONDARY outcome

Timeframe: Day 169

Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.

The ADAS-Cog11 total score = the sum of all 11 individual items (word recall \[10\]; commands \[5\]; constructional praxis \[5\]; naming objects and fingers \[5\]; ideational praxis \[5\]; orientation \[8\]; word recognition \[12\]; remembering test instructions \[5\]; spoken language \[5\]; word finding \[5\]; and comprehension of spoken language \[5\]). The score range for ADAS-cog 11 is 0-70 where a higher score is worse performance. The ADAS-cog methodology is to sum scores for subscales. The results were calculated using the average change from baseline. Baseline is defined as the last measurement taken before the first dose of study drug is administered. Change is calculated as the observed value minus the baseline value. A negative change from baseline indicates improvement.

Outcome measures

Outcome measures
Measure
300 mg
n=8 Participants
High Dose CT1812 CT1812 300 mg
100 mg
n=8 Participants
Low Dose CT1812 CT1812 100 mg
Placebo
n=7 Participants
Matching Placebo
All Subjects
Total
Change From Baseline ADAS-Cog11 (Alzheimer's Disease Assessment Scale - Cognition Subscale)
1.78 score on a scale
Standard Error 2.101
1.28 score on a scale
Standard Error 2.091
1.37 score on a scale
Standard Error 2.144

SECONDARY outcome

Timeframe: Day 169

Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.

The ADAS-Cog13 total score includes all of the items in the ADAS-Cog11 and the delayed word recall and the number cancellation. For the ADAS-cog 13 the range is 0-85 (score range for Delayed Word Recall \[DWR\] score is 0-10 and for Number Cancellation \[NC\] is 0-5, thus the score is ADAS-cog 11\[0-70\] plus the scores for DWR and NC). A higher score indicates worse performance. The ADAS-cog methodology is to sum scores for subscales. The results were calculated using the average change from baseline. Baseline is defined as the last measurement taken before the first dose of study drug. Change is calculated as the observed value minus the baseline value. A negative change from baseline indicates improvement in cognitive function.

Outcome measures

Outcome measures
Measure
300 mg
n=8 Participants
High Dose CT1812 CT1812 300 mg
100 mg
n=8 Participants
Low Dose CT1812 CT1812 100 mg
Placebo
n=7 Participants
Matching Placebo
All Subjects
Total
Change From Baseline ADAS-Cog13 (Alzheimer's Disease Assessment Scale - Cognition Subscale)
2.62 score on a scale
Standard Error 2.157
1.73 score on a scale
Standard Error 2.146
1.02 score on a scale
Standard Error 2.178

SECONDARY outcome

Timeframe: Day 169

Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.

The ADAS-Cog14 total score includes all of the items in the ADAS-Cog13 \[0-85\] and the maze item which has a score range of 0-5. Thus, the total score for the ADAS-cog 14 is 0-90 where again a higher score is worst performance. The ADAS-cog methodology is to sum scores for subscales. The results were calculated using the average change from baseline. Baseline is defined as the last measurement taken before the first dose of study drug is administered. Change is calculated as the observed value minus the baseline value. A negative change from baseline indicates improvement in cognitive function.

Outcome measures

Outcome measures
Measure
300 mg
n=8 Participants
High Dose CT1812 CT1812 300 mg
100 mg
n=8 Participants
Low Dose CT1812 CT1812 100 mg
Placebo
n=7 Participants
Matching Placebo
All Subjects
Total
Change From Baseline ADAS-Cog14 (Alzheimer's Disease Assessment Scale - Cognition Subscale)
1.25 score on a scale
Standard Error 2.544
1.42 score on a scale
Standard Error 2.245
1.65 score on a scale
Standard Error 2.290

SECONDARY outcome

Timeframe: Day 169

Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.

The ADCS-ADL is a 23-item informant-administered assessment of functional impairment in terms of activities of daily living. Informants respond to 23 questions about the subject's involvement and level of performance across items representing daily living. The questions range from basic to instrumental activities of daily living. Each item is rated from the highest level of independent performance to complete loss. The total score range is from 0-78 with lower scores indicating greater functional impairment. A positive change from baseline indicates improvement in function. The results were calculated using the average change from baseline. Higher scores mean better outcome. Negative mean indicates worsening of function. Positive mean indicates improvement of function.

Outcome measures

Outcome measures
Measure
300 mg
n=8 Participants
High Dose CT1812 CT1812 300 mg
100 mg
n=8 Participants
Low Dose CT1812 CT1812 100 mg
Placebo
n=7 Participants
Matching Placebo
All Subjects
Total
Change From Baseline in ADCS-Activities of Daily Living (ADCS-ADL)
-3.16 score on a scale
Standard Error 1.646
-0.31 score on a scale
Standard Error 1.522
2.21 score on a scale
Standard Error 1.641

SECONDARY outcome

Timeframe: Day 169

Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.

The MMSE assesses several aspects of memory and cognitive functioning including orientation, attention, concentration, comprehension, recall, and praxis. The total possible score is 30, with high scores indicating less impairment. Change from baseline is calculated as the observed value minus the baseline value. A positive change from baseline indicates improvement in cognition.

Outcome measures

Outcome measures
Measure
300 mg
n=8 Participants
High Dose CT1812 CT1812 300 mg
100 mg
n=8 Participants
Low Dose CT1812 CT1812 100 mg
Placebo
n=7 Participants
Matching Placebo
All Subjects
Total
Change From Baseline in Mini Mental State Exam (MMSE)
-2.92 score on a scale
Standard Error 1.540
-1.26 score on a scale
Standard Error 1.448
-0.74 score on a scale
Standard Error 1.547

SECONDARY outcome

Timeframe: Day 169

Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.

Scores were on a scale of 0 through 3, with 0=no dementia, 0.5=questionable dementia, 1=mild dementia, 2=moderate dementia, and 3=severe dementia. Cognitive and functional abilities that were assessed include Memory; Orientation; Judgment and Problem Solving; Community Affairs; Home and Hobbies; and Personal Care. Memory was considered as the primary driver for scoring and the other categories were secondary. The change from baseline in the CDR-SB total score was analyzed using the mixed model for repeated measures (MMRM). Change from baseline is calculated as the observed value minus the baseline value. Higher scores mean worsening of disease.

Outcome measures

Outcome measures
Measure
300 mg
n=8 Participants
High Dose CT1812 CT1812 300 mg
100 mg
n=8 Participants
Low Dose CT1812 CT1812 100 mg
Placebo
n=7 Participants
Matching Placebo
All Subjects
Total
Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)
0.72 score on a scale
Standard Error 0.421
0.39 score on a scale
Standard Error 0.399
0.17 score on a scale
Standard Error 0.409

SECONDARY outcome

Timeframe: Day 169

Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.

The scale consists of a format with which a clinician may address clinically relevant overall change, including 15 areas under the domains of cognition, behavior, and social and daily functioning. For ADCS-CGIC, the individual data listing presented the original score on the seven-point scale. In addition, the seven-point score was collapsed to 3 groups, combining scores 1-3 to "Improved", 4 to "No change", and 5-7 to "Worsening". Lower scores indicate improvement.

Outcome measures

Outcome measures
Measure
300 mg
n=8 Participants
High Dose CT1812 CT1812 300 mg
100 mg
n=8 Participants
Low Dose CT1812 CT1812 100 mg
Placebo
n=7 Participants
Matching Placebo
All Subjects
Total
Change From Baseline in Alzheimer's Disease Clinical Study - Clinician Global Impression of Change (ADCS-CGIC)
4.80 score on a scale
Standard Error 0.279
4.50 score on a scale
Standard Error 0.257
4.68 score on a scale
Standard Error 0.257

SECONDARY outcome

Timeframe: Day169

Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.

The Cognitive composite included: 1. 6 ADAS-Cog items: word recall, orientation, delayed word recall, word recognition, number cancellation, and maze 2. 4 Neuropsychological Test Battery (NTB) items: Trail Making Test (TMT) A, Trail Making Test (TMT) B, Category Fluency Test (CFT), Digit span. Each individual z-score was calculated by first computing the baseline mean and standard deviation at baseline for all subjects within each individual component. The z-scores were then derived for each subject and timepoint by subtracting the corresponding baseline mean from the observed value and then dividing by the standard deviation at baseline. The sign of the z-score for the following components was reversed when deriving the Composite scores: Word recall, Orientation, Delayed Word Recall, Word Recognition, Maze, TMT A, TMT B. Z-score = 0 represents the population at baseline Positive Z-score = indicates improvement Negative Z-score= indicates worsening

Outcome measures

Outcome measures
Measure
300 mg
n=8 Participants
High Dose CT1812 CT1812 300 mg
100 mg
n=8 Participants
Low Dose CT1812 CT1812 100 mg
Placebo
n=7 Participants
Matching Placebo
All Subjects
Total
Change From Baseline in the Cognitive Composite
-0.33 Z-Score
Standard Error 0.109
-0.11 Z-Score
Standard Error 0.102
-0.10 Z-Score
Standard Error 0.109

SECONDARY outcome

Timeframe: Day169

Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.

The memory composite includes 4 ADAS-COG (Alzheimer's Disease Assessment Scale - cognition subscale) items: word recall, orientation, delayed word recall, word recognition. The Memory composite score will be a composite z-score average similar to the Cognitive Composite score but will only be derived using the average of the ADAS-Cog Word Recall, Orientation, Delayed Word Recall, and Word Recognition items. If a subject is missing any of the four items at a timepoint, this composite score will not be derived. The score was calculated using z-scores of the items cited above where: Z-score = 0 represents the population at baseline. Positive Z-score = indicates improvement Negative Z-score= indicates worsening

Outcome measures

Outcome measures
Measure
300 mg
n=8 Participants
High Dose CT1812 CT1812 300 mg
100 mg
n=8 Participants
Low Dose CT1812 CT1812 100 mg
Placebo
n=7 Participants
Matching Placebo
All Subjects
Total
Change From Baseline in the Memory Composite
-0.49 Z-score
Standard Error 0.201
-0.18 Z-score
Standard Error 0.201
-0.14 Z-score
Standard Error 0.198

SECONDARY outcome

Timeframe: Day 169

Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.

The Attention composite score included: 1. 1 ADAS-COG (Alzheimer's Disease Assessment Scale -cognition subscale) item: Number Cancellation 2. 1 NTB item: Trail Making Test (TMT) A The Attention composite score will be a composite z-score average derived using the average of the Number Cancellation, Maze item from ADAS-Cog 14, and TMT A items. If a subject missed either of the three items at a timepoint, this composite score was derived. The score was calculated using z-scores of the items cited above where: Z-score = 0 represents the population at baseline. Positive Z-score = indicates improvement Negative Z-score= indicates worsening

Outcome measures

Outcome measures
Measure
300 mg
n=8 Participants
High Dose CT1812 CT1812 300 mg
100 mg
n=8 Participants
Low Dose CT1812 CT1812 100 mg
Placebo
n=7 Participants
Matching Placebo
All Subjects
Total
Change From Baseline in Attention Composite
-0.01 Z-score
Standard Error 0.158
0.15 Z-score
Standard Error 0.132
-0.13 Z-score
Standard Error 0.139

SECONDARY outcome

Timeframe: Day 169

Population: All patients who received at least one dose of investigational product and had a post-baseline assessment of any of the cognitive and clinical endpoints.

The Executive composite included 1. 0 ADAS-COG (Alzheimer's Disease Assessment Scale - cognition subscale) items 2. 3 NTB (Neuropsychological Test Battery) items: CFT (Category Fluency Test), Digit Span, and Trail Making Test (TMT) B The Executive function composite score will be a composite z-score average derived using the average of the CFT Category Fluency Test), Digit Span, and TMT B items. If a subject is missing any of the three items at a timepoint, this composite score will not be derived. The score was calculated using z-scores of the items cited above where: Z-score = 0 represents the population at baseline. Positive Z-score = indicates improvement Negative Z-score= indicates worsening

Outcome measures

Outcome measures
Measure
300 mg
n=8 Participants
High Dose CT1812 CT1812 300 mg
100 mg
n=8 Participants
Low Dose CT1812 CT1812 100 mg
Placebo
n=7 Participants
Matching Placebo
All Subjects
Total
Change From Baseline in the Executive Composite
-0.35 Z-score
Standard Error 0.366
0.66 Z-score
Standard Error 0.364
-0.03 Z-score
Standard Error 0.256

Adverse Events

300 mg

Serious events: 0 serious events
Other events: 7 other events
Deaths: 0 deaths

100 mg

Serious events: 3 serious events
Other events: 8 other events
Deaths: 0 deaths

Placebo

Serious events: 1 serious events
Other events: 6 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
300 mg
n=8 participants at risk
High Dose CT1812 CT1812 300 mg
100 mg
n=8 participants at risk
Low Dose CT1812 CT1812 100 mg
Placebo
n=7 participants at risk
Matching Placebo
Renal and urinary disorders
Ureterolithiasis
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Nervous system disorders
Thalamic Infarction
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Psychiatric disorders
Psychotic disorder
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Nervous system disorders
Seizure
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Infections and infestations
Encephalitis
0.00%
0/8 • Up to 12 months
0.00%
0/8 • Up to 12 months
14.3%
1/7 • Number of events 1 • Up to 12 months

Other adverse events

Other adverse events
Measure
300 mg
n=8 participants at risk
High Dose CT1812 CT1812 300 mg
100 mg
n=8 participants at risk
Low Dose CT1812 CT1812 100 mg
Placebo
n=7 participants at risk
Matching Placebo
Infections and infestations
Bronchitis
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/8 • Up to 12 months
0.00%
0/7 • Up to 12 months
Infections and infestations
Encephalitis
0.00%
0/8 • Up to 12 months
0.00%
0/8 • Up to 12 months
14.3%
1/7 • Number of events 1 • Up to 12 months
Infections and infestations
Furuncle
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Infections and infestations
Upper respiratory tract infection
0.00%
0/8 • Up to 12 months
25.0%
2/8 • Number of events 4 • Up to 12 months
0.00%
0/7 • Up to 12 months
Infections and infestations
Urinary tract infection
0.00%
0/8 • Up to 12 months
25.0%
2/8 • Number of events 2 • Up to 12 months
0.00%
0/7 • Up to 12 months
Blood and lymphatic system disorders
Anaemia
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Endocrine disorders
Goitre
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/8 • Up to 12 months
0.00%
0/7 • Up to 12 months
Endocrine disorders
Inappropriate antidiuretic hormone secretion
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Metabolism and nutrition disorders
Hyperlipidaemia
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/8 • Up to 12 months
0.00%
0/7 • Up to 12 months
Metabolism and nutrition disorders
Hyponatraemia
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Psychiatric disorders
Confusional state
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/8 • Up to 12 months
0.00%
0/7 • Up to 12 months
Psychiatric disorders
Psychotic disorder
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Nervous system disorders
Carotid artery stenosis
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/8 • Up to 12 months
0.00%
0/7 • Up to 12 months
Nervous system disorders
Cerebral ischaemia
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/8 • Up to 12 months
0.00%
0/7 • Up to 12 months
Nervous system disorders
Cerebral microhaemorrhage
0.00%
0/8 • Up to 12 months
0.00%
0/8 • Up to 12 months
14.3%
1/7 • Number of events 1 • Up to 12 months
Nervous system disorders
Dizziness
12.5%
1/8 • Number of events 3 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Nervous system disorders
Headache
37.5%
3/8 • Number of events 3 • Up to 12 months
25.0%
2/8 • Number of events 2 • Up to 12 months
28.6%
2/7 • Number of events 2 • Up to 12 months
Nervous system disorders
Seizure
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Nervous system disorders
Thalamic infarction
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Eye disorders
Eye pain
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/8 • Up to 12 months
0.00%
0/7 • Up to 12 months
Vascular disorders
Peripheral venous disease
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Respiratory, thoracic and mediastinal disorders
Cough
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 2 • Up to 12 months
0.00%
0/7 • Up to 12 months
Gastrointestinal disorders
Diarrhoea
0.00%
0/8 • Up to 12 months
0.00%
0/8 • Up to 12 months
14.3%
1/7 • Number of events 1 • Up to 12 months
Gastrointestinal disorders
Gastrooesophageal reflux disease
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Gastrointestinal disorders
Vomiting
0.00%
0/8 • Up to 12 months
25.0%
2/8 • Number of events 2 • Up to 12 months
14.3%
1/7 • Number of events 1 • Up to 12 months
Skin and subcutaneous tissue disorders
Swelling face
0.00%
0/8 • Up to 12 months
0.00%
0/8 • Up to 12 months
14.3%
1/7 • Number of events 1 • Up to 12 months
Musculoskeletal and connective tissue disorders
Arthralgia
0.00%
0/8 • Up to 12 months
0.00%
0/8 • Up to 12 months
14.3%
1/7 • Number of events 1 • Up to 12 months
Musculoskeletal and connective tissue disorders
Back pain
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/8 • Up to 12 months
0.00%
0/7 • Up to 12 months
Musculoskeletal and connective tissue disorders
Neck pain
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/8 • Up to 12 months
0.00%
0/7 • Up to 12 months
Renal and urinary disorders
Micturition urgency
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Renal and urinary disorders
Pollakiuria
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Investigations
Liver function test increased
25.0%
2/8 • Number of events 2 • Up to 12 months
0.00%
0/8 • Up to 12 months
0.00%
0/7 • Up to 12 months
Injury, poisoning and procedural complications
Ankle fracture
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/8 • Up to 12 months
14.3%
1/7 • Number of events 1 • Up to 12 months
Injury, poisoning and procedural complications
Tooth fracture
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Injury, poisoning and procedural complications
Fall
12.5%
1/8 • Number of events 2 • Up to 12 months
12.5%
1/8 • Number of events 4 • Up to 12 months
14.3%
1/7 • Number of events 1 • Up to 12 months
Surgical and medical procedures
Carotid endarterectomy
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/8 • Up to 12 months
0.00%
0/7 • Up to 12 months
Infections and infestations
Cellulitis
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/8 • Up to 12 months
0.00%
0/7 • Up to 12 months
Infections and infestations
Nasopharyngitis
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/8 • Up to 12 months
0.00%
0/7 • Up to 12 months
Infections and infestations
Pneumonia
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Metabolism and nutrition disorders
Hyperglycaemia
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Psychiatric disorders
Anxiety
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Nervous system disorders
Cerebral Infarction
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Gastrointestinal disorders
Constipation
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Gastrointestinal disorders
Nausea
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Renal and urinary disorders
Hypertonic bladder
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Renal and urinary disorders
Ureterolithiasis
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Injury, poisoning and procedural complications
Ligament Sprain
0.00%
0/8 • Up to 12 months
0.00%
0/8 • Up to 12 months
14.3%
1/7 • Number of events 1 • Up to 12 months
Surgical and medical procedures
Cataract Operation
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 2 • Up to 12 months
0.00%
0/7 • Up to 12 months
Surgical and medical procedures
Gingival graft
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months
Surgical and medical procedures
Ureatric Operation
0.00%
0/8 • Up to 12 months
12.5%
1/8 • Number of events 1 • Up to 12 months
0.00%
0/7 • Up to 12 months

Additional Information

Chief Medical Officer, Head of R&D

Cogntion Therapeutics Inc

Phone: 914-221-6730

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place